BN Business News
Bedrijf toevoegen →
Deze vertaling wordt voorbereid. Voorlopig tonen we de oorspronkelijke Engelse versie.

Bedrijven · 1-6-20071 min lezen

Determination of Regulatory Review Period for Purposes of Patent Extension; GEM 21S GROWTH-FACTOR ENHANCED MATRIX

Lokale automatische vertaling · Oorspronkelijke brontaal

Samenvatting

The Food and Drug Administration (FDA) has determined the regulatory review period for GEM 21S GROWTH-FACTOR ENHANCED MATRIX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.

Oorspronkelijke brontaal: Federal Register — Food and Drug AdministrationOrigineel bericht openen →